Abstract

Objective To investigate the clinical pathological characteristics and prognosis of primitive neuroectodermal tumor (PNET) of breast. Methods Patients with breast PNET were retrieved from CNKI, Pubmed, Europe PMC and other databases from Jan. 1980 to Dec. 2016. The clinical data of one patient with breast PNET in our hospital were analyzed retrospectively. Results 18 cases had painless, rapid growth mass as the main clinical features. The pathological morphology showed small round cell tumors, PAS staining positive. Immunohistochemistry CD99 and Fli-1 characteristic expression were the main indexes for the diagnosis of breast PNET. The positive expression of Vimentin, NSE, Syn and negative expression of CK, EMA, Desmin, CgA, LCA, S-100 also played an important role in the diagnosis of breast PNET. The positive expression of genetic marker EWSRI was the golden standard for diagnosis of breast PNET. The size of the tumor, surgical treatment, lymph node metastasis, distant metastasis and chemotherapy were the important factors that affect the prognosis of the PNET. The survival rates of 1 and 3 years were 71.4% and 33.3% respectively. Conclusions Breast PNET is a rare tumor with poor prognosis, and its diagnosis is highly dependent on pathology. Surgery can significantly improve the prognosis of the patients. Surgery should be the main treatment, combined with radiotherapy and chemotherapy. The current study does not show evidence of effectiveness in terms of endocrine or targeted drug therapy for breast PNET patients. Key words: Breast; Primitive neuroectodermal tumor; Clinical Pathology; Prognosis analysis

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.